From: Vape News
By John Castle
The Hurdles In iQOS’ Way
The biggest regulatory hurdle Philip Morris International faces in bringing the iQOS to the U.S. market comes from the U.S. Food & Drug Administration (FDA).
While a committee which advises the FDA has urged that FDA deny PMI’s “modified-risk” claim for the product, it should be remembered that how PMI is permitted to advertise the product on the U.S. market, and whether or not PMI is permitted to sell the product on the U.S. market, are entirely